| Product Name | MF | CAS | Details |
|---|
| Anti-NGF / bNGF Reference Antibody (AS2886401-00) | Details |
| Anti-NGF / bNGF Reference Antibody (fasinumab) | Details |
| Anti-NGF / bNGF Reference Antibody (fulranumab) | Details |
| Anti-NGF / bNGF Reference Antibody (MEDI-578) | Details |
| Anti-NGF / bNGF Reference Antibody (PG110) | Details |
| Anti-NGF / bNGF Reference Antibody (tanezumab) | Details |
| Anti-NKG2A / CD159a Reference Antibody (monalizumab) | Details |
| Anti-NKG2D / CD314 Reference Antibody (tesnatilimab) | Details |
| Anti-Nogo Receptor / NgR Reference Antibody (Abbott patent anti-NGR) | Details |
| Anti-NOTCH1 Reference Antibody (brontictuzumab) | Details |
| Anti-NOTCH1 Reference Antibody (Pfizer patent anti-Notch1) | Details |
| Anti-NOTCH3 Reference Antibody (Genentech patent anti-Notch3) | Details |
| Anti-NOTCH3 Reference Antibody (tarextumab) | Details |
| Anti-NRP1 / VEGF165R / CD304 Reference Antibody (vesencumab) | Details |
| Anti-NT5E / CD73 Reference Antibody (mupadolimab) | Details |
| Anti-NT5E / CD73 Reference Antibody (oleclumab) | Details |
| Anti-NT5E / CD73 Reference Antibody (uliledlimab) | Details |
| Anti-Nucleocapsid Antibody (N-18) | Details |
| Anti-Nucleocapsid Antibody (N-9) | Details |
| Anti-Nucleocapsid Antibody (N-P10) | Details |
| Anti-Nucleocapsid Antibody (N-P11) | Details |
| Anti-Orai1 Reference Antibody (Amgen patent anti-ORAI1) | Details |
| Anti-OSMR Reference Antibody (vixarelimab) | Details |
| Anti-Osteopontin Reference Antibody (ASK8007) | Details |
| Anti-OX2R / CD200R1 Reference Antibody (Janssen patent anti-CD200R1) | Details |
| Anti-oxLDL Reference Antibody (Okayama U. patent anti-oxLDL) | Details |
| Anti-oxLDL Reference Antibody (orticumab) | Details |
| Anti-PAC1 Reference Antibody (zelminemab) | Details |
| Anti-PACAP38 Reference Antibody (Lilly patent anti-PACAP) | Details |
| Anti-PAR2 Reference Antibody (Amgen patent anti-PAR-2) | Details |
| Anti-PAR2 Reference Antibody (PAR650097) | Details |
| Anti-PAR2 Reference Antibody (Regeneron patent anti-PAR-2) | Details |
| Anti-PCLA Reference Antibody (U.Penn. patent anti-PCLA) | Details |
| Anti-PCSK9 Reference Antibody (alirocumab) | Details |
| Anti-PCSK9 Reference Antibody (bococizumab) | Details |
| Anti-PCSK9 Reference Antibody (Boehringer anti-PCSK9) | Details |
| Anti-PCSK9 Reference Antibody (ebronucimab) | Details |
| Anti-PCSK9 Reference Antibody (evolocumab) | Details |
| Anti-PCSK9 Reference Antibody (frovocimab) | Details |
| Anti-PCSK9 Reference Antibody (lodelcizumab) | Details |
| Anti-PCSK9 Reference Antibody (Merck patent anti-PCSK9) | Details |
| Anti-PCSK9 Reference Antibody (ongericimab) | Details |
| Anti-LAP Reference Antibody (Brigham and Womens anti-LAP) | Details |
| Anti-LEPR / CD295 Reference Antibody (mibavademab) | Details |
| Anti-Lewis Y Reference Antibody (MB 311) | Details |
| Anti-LIF Reference Antibody (MSC-1) | Details |
| Anti-LILRB2 / ILT4 / CD85d Reference Antibody (JTX-8064) | Details |
| Anti-LILRB4 / ILT3 / CD85k Reference Antibody (Merck patent anti-ILT3 complex) | Details |
| Anti-LILRB4 / ILT3 / CD85k Reference Antibody (U.Texas patent anti-LILRB4) | Details |
| Anti-LINGO1 Reference Antibody (opicinumab) | Details |
| Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumAb) | Details |
| Anti-LOXL2 Reference Antibody (simtuzumab) | Details |
| Anti-LRRC15 / LIB Reference Antibody (samrotamab) | Details |
| Anti-Ly6E Reference Antibody (RG7841) | Details |
| Anti-LY75 / CD205 Reference Antibody (CDX-1401) | Details |
| Anti-LY75 / CD205 Reference Antibody (MEN1309) | Details |
| Anti-LYPD3 / C4.4A Reference Antibody (lupartumab) | Details |
| Anti-MADCAM1 Reference Antibody (ontamalimab) | Details |
| Anti-MAGEA3 Reference Antibody (CT Atlantic patent anti-MAGE-A3) | Details |
| Anti-MASP2 Reference Antibody (narsoplimab) | Details |
| Anti-Matriptase Reference Antibody (Oxford Bio patent anti-Matriptase) | Details |
| Anti-Melanotransferrin / CD228 Reference Antibody (SC-005) | Details |
| Anti-MER / MERTK Reference Antibody (RGX-019) | Details |
| Anti-MERS Reference Antibody (2E6) | Details |
| Anti-MERS Reference Antibody (3A1) | Details |
| Anti-MERS Reference Antibody (D12) | Details |
| Anti-Mesothelin Reference Antibody (amatuximab) | Details |
| Anti-Mesothelin Reference Antibody (anetumab) | Details |
| Anti-Mesothelin Reference Antibody (BMS-986148) | Details |
| Anti-Mesothelin Reference Antibody (NIH patent anti-Mesothelin) | Details |
| Anti-MICA Reference Antibody (CLN-619) | Details |
| Anti-MMP9 Reference Antibody (Yeda patent anti-MMP-9) | Details |
| Anti-MUC5AC Reference Antibody (ensituximab) | Details |
| Anti-MICB Reference Antibody (U.Washington patent anti-MICB) | Details |
| Anti-MUC16 Reference Antibody (sofituzumab) | Details |
| Anti-NCAM1 / CD56 Reference Antibody (lorvotuzumab) | Details |
| Anti-LAG3 / CD223 Reference Antibody (ieramilimab) | Details |
| Anti-MSPR / RON / CD136 Reference Antibody (Aveo anti-RON) | Details |
| Anti-MUC1 Reference Antibody (gatipotuzumab) | Details |
| Anti-LAG3 / CD223 Reference Antibody (encelimab) | Details |
| Anti-MPL / TPOR / CD110 Reference Antibody (TA136) | Details |
| Anti-MUSK Reference Antibody (Argenx patent anti-MuSK) | Details |
| Anti-MIF Reference Antibody (imalumab) | Details |
| Anti-MUC17 Reference Antibody (Forerunner patent anti-Muc 17) | Details |
| Anti-Nectin-4 Reference Antibody (enfortumab) | Details |
| Anti-LAG3 / CD223 Reference Antibody (miptenalimab) | Details |
| Anti-MSPR / RON / CD136 Reference Antibody (narnatumab) | Details |
| Anti-MUC16 Reference Antibody (abagovomab) | Details |
| Anti-LAG3 / CD223 Reference Antibody (favezelimab) | Details |
| Anti-LAMP1 / CD107a Reference Antibody (SAR428926) | Details |
| Anti-MRC2 / CD280 Reference Antibody (Copenhagen Rigshospitalet patent anti-uPARAP) | Details |
| Anti-MUC1 Reference Antibody (cantuzumab) | Details |
| Anti-MMP9 Reference Antibody (andecaliximab) | Details |
| Anti-MUC18 / MCAM / CD146 Reference Antibody (imaprelimab) | Details |
| Anti-LAG3 / CD223 Reference Antibody (relatlimab) | Details |
| Anti-MUC1 Reference Antibody (AR20.5) | Details |
| Anti-MUC16 Reference Antibody (oregovomab) | Details |
| Anti-LAG3 / CD223 Reference Antibody (fianlimab) | Details |
| Anti-MRC2 / CD280 Reference Antibody (Quark patent anti-ENDO 180) | Details |
| Anti-MUC1 Reference Antibody (clivatuzumab) | Details |
| Product Total： Product Page： | ||||
| 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 | ||||